Publication
Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.
Orazio Caffo, Umberto Basso, Gaetano Facchini, Donatello Gasparro, Daniele Alesini, Marcello Tucci, Cinzia Ortega, Lucia Fratino, Enrico Campadelli, Giovanni Lo Re, Roberto Sabbatini, Giuseppe Procopio, Paolo A. Zucali, Alessandro D'Angelo, Maddalena Donini, Francesco Massari, Raffaele Ratta, Teodoro Sava, Caterina Messina, Ugo De Giorgi
Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2014.32.15_suppl.5089